Download PDF
Am J Perinatol 2014; 31(08): 673-676
DOI: 10.1055/s-0033-1357264
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Oliguria during Hydrocortisone Dosage Wean in Very Low Birth Weight Infants

J. B. Sauberan
1   Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, California
,
E. M. Reed
1   Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, California
,
Y. V. Vaucher
1   Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, California
,
A. C. Katheria
1   Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, California
2   Department of Neonatology, Sharp Mary Birch Hospital for Women and Newborns, San Diego, California
› Author Affiliations
Further Information

Publication History

11 June 2013

13 August 2013

Publication Date:
09 October 2013 (online)

    Permissions and Reprints

Abstract

Background Intravenous hydrocortisone (HC) is often used in very low birth weight infants (VLBW) but can be complicated by oliguria when discontinued or tapered.

Objectives To determine which factors were associated with oliguria during HC taper.

Methods We reviewed all VLBW infants who received initial doses of HC ≥ 1 mg/kg/d. The initial dose and duration of HC, and the incidence of oliguria (urine output [UO] < 2 mL/kg/h) during HC taper, were recorded. In those with oliguria, we recorded the change in UO (mL/kg/h), blood pressure, and creatinine.

Results The mean initial HC dose was 2.8 ± 1 mg/kg/d, and the mean total duration of HC therapy was 23 ± 25 days. Oliguria occurred in 24% (13/54) of treated infants. These infants were exposed to higher and longer duration of the initial HC dose than infants without oliguria. Oliguria was predicted by the initial HC dose (odds ratio [OR] 5.8, 95% confidence interval [CI] 1.3–25.8, p = 0.02) and by the number of days at initial dose (OR 1.7, 95%CI 1.1–2.7, p = 0.03).

Conclusions Oliguria during HC dosage weaning was associated with higher initial HC exposure.

Keywords

hydrocortisone - hypotension - neonate - renal failure - renal dysfunction - oliguria - steroids - very low birth weight infants
 

  • References

  • 1 Finer NN, Powers RJ, Ou CH, Durand D, Wirtschafter D, Gould JB ; California Perinatal Quality Care Collaborative Executive Committee. Prospective evaluation of postnatal steroid administration: a 1-year experience from the California Perinatal Quality Care Collaborative. Pediatrics 2006; 117 (3) 704-713
    CrossrefPubMedGoogle Scholar
  • 2 Onland W, Offringa M, Cools F , et al. Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial. BMC Pediatr 2011; 11 (11) 102
    CrossrefPubMedGoogle Scholar
  • 3 Watterberg KL ; American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement—postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126 (4) 800-808
    CrossrefPubMedGoogle Scholar
  • 4 Peltoniemi OM, Lano A, Puosi R , et al; Neonatal Hydrocortisone Working Group. Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology 2009; 95 (3) 240-247
    CrossrefPubMedGoogle Scholar
  • 5 Henwood MJ, Levitt-Katz LE. Disorders of the adrenal gland. In: Moshang T, , ed. Pediatric Endocrinology: The Requisites in Pediatrics. St. Louis: Mosby; 2005: 193-216
    CrossrefGoogle Scholar
  • 6 Fernandez EF, Watterberg KL. Relative adrenal insufficiency in the preterm and term infant. J Perinatol 2009; 29 (Suppl. 02) S44-S49
    CrossrefPubMedGoogle Scholar
  • 7 Ng PC, Lee CH, Lam CW , et al. Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2004; 89 (2) F119-F126
    CrossrefPubMedGoogle Scholar
  • 8 Hochwald O, Holsti L, Osiovich H. The use of an early ACTH test to identify hypoadrenalism-related hypotension in low birth weight infants. J Perinatol 2012; 32 (6) 412-417
    CrossrefPubMedGoogle Scholar
  • 9 Watterberg K. Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. Clin Perinatol 2012; 39 (1) 47-59
    CrossrefPubMedGoogle Scholar
  • 10 Ibrahim H, Sinha IP, Subhedar NV. Corticosteroids for treating hypotension in preterm infants. Cochrane Database Syst Rev 2011; (12, Issue 12): CD003662
    PubMedGoogle Scholar
  • 11 Bourchier D, Weston PJ. Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1997; 76 (3) F174-F178
    CrossrefPubMedGoogle Scholar
  • 12 Efird MM, Heerens AT, Gordon PV, Bose CL, Young DA. A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. J Perinatol 2005; 25 (2) 119-124
    CrossrefPubMedGoogle Scholar
  • 13 Watterberg KL, Gerdes JS, Cole CH , et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004; 114 (6) 1649-1657
    Google Scholar
  • 14 Peltoniemi O, Kari MA, Heinonen K , et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 2005; 146 (5) 632-637
    CrossrefPubMedGoogle Scholar
  • 15 Bonsante F, Latorre G, Iacobelli S , et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology 2007; 91 (4) 217-221
    CrossrefPubMedGoogle Scholar